Filtros de búsqueda

Lista de obras de

2 Gy × 2 for palliative treatment of mantle cell lymphoma

artículo científico publicado en 2016

A 3-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408

artículo científico publicado en 2020

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma

artículo científico publicado en 2014

A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma

artículo científico publicado en 2004

A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study.

artículo científico publicado en 2013

A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.

artículo científico publicado en 2014

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer

artículo científico publicado en 2005

A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies

artículo científico publicado en 2011

A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial

artículo científico publicado en 2015

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

artículo científico publicado en 2014

A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402

artículo científico publicado en 2015

A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis

artículo científico publicado en 2016

A prospective cohort study of patients with peripheral T-cell lymphoma in the United States

artículo científico publicado en 2016

A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy

artículo científico publicado en 2015

ABCL-455 Multicenter Retrospective Analysis of Single-Route Prophylaxis in Aggressive B-Cell Lymphomas

ACR Appropriateness Criteria Pediatric Hodgkin Lymphoma

artículo científico

ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma

artículo científico

ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II.

artículo científico publicado en 2016

ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II.

artículo científico publicado en 2016

ACR Appropriateness Criteria® on Hodgkin's lymphoma-unfavorable clinical stage I and II.

scientific article published on May 2011

ACR appropriateness criteria follow-up of Hodgkin lymphoma.

artículo científico

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.

artículo científico publicado en 2017

Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma

Advances in the management of primary mediastinal large B-cell lymphoma

artículo científico publicado en 2018

Age, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network

Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

artículo científico publicado en 2015

Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation

artículo científico publicado en 2018

Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States

artículo científico publicado en 2017

Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine

scientific article published on 01 March 2007

Anti-CD30 antibody–drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives

Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study

Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT).

artículo científico publicado en 2015

Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study

Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial

scientific article published on 01 September 2020

Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).

artículo científico publicado en 2013

Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development

artículo científico publicado en 2008

Breast Imaging in Women Previously Irradiated for Hodgkin Lymphoma

artículo científico publicado en 2014

Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

scientific article published on 07 January 2019

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

artículo científico publicado en 2012

Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry

artículo científico publicado en 2016

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.

artículo científico publicado en 2015

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies ⬇️

artículo científico publicado el 30 de mayo de 2013

Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study

artículo científico publicado en 2014

Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies

artículo científico publicado en 2012

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

artículo científico publicado en 2018

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

artículo científico publicado en 2018

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

scientific article published on 01 March 2020

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

artículo científico publicado en 2012

Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas

artículo científico publicado en 2013

Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma

artículo científico publicado en 2016

Bulky mediastinal classical Hodgkin lymphoma in young women

artículo científico publicado en 2014

CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center

artículo científico publicado en 2020

CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity

artículo científico publicado en 2022

CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma

artículo científico publicado en 2011

CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma

artículo científico publicado en 2019

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma

scientific article published on 01 November 2018

Cancer vaccines and T cell therapy

artículo científico publicado en 2013

Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial

artículo científico publicado en 2011

Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience

Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience

Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy

artículo científico publicado en 2020

Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy

scientific article published on 19 May 2020

Checkpoint inhibitor‐based salvage regimens prior to autologous stem cell transplant improve event‐free survival in relapsed/refractory classic Hodgkin lymphoma

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015

artículo científico publicado en 2015

Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma

artículo científico publicado en 2018

Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status

artículo científico publicado en 2016

Clinical Impact of the 2016 Update to the WHO Lymphoma Classification

artículo científico publicado en 2017

Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood a

scientific article published on 07 August 2017

Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia

artículo científico publicado en 2015

Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognos

artículo científico publicado en 2010

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic

scientific article published on 30 July 2020

Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia

artículo científico publicado en 2020

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL

scientific article published on 04 June 2019

Current concepts and controversies in the management of early stage Hodgkin lymphoma

artículo científico publicado en 2011

Customized targeted therapy in Hodgkin lymphoma: hype or hope?

artículo científico publicado en 2014

Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiology

artículo científico publicado en 2006

DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set

artículo científico publicado en 2021

Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind,

artículo científico publicado en 2015

Diffuse Large B-Cell Lymphoma Version 1.2016

scientific article published on 01 February 2016

Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring

artículo científico publicado en 2016

Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.

artículo científico publicado en 2016

Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma

artículo científico publicado en 2013

Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88L265P Mutation

artículo científico publicado en 2017

Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease

artículo científico publicado en 2009

Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial ⬇️

artículo científico publicado el 7 de noviembre de 2012

End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making

scientific article published on 10 May 2018

Epstein-Barr virus-associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin's lymphoma

artículo científico publicado en 1993

Erratum to: Clinical Impact of the 2016 Update to the WHO Lymphoma Classification

artículo científico publicado en 2017

Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies.

artículo científico publicado en 2008

Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era

artículo científico publicado en 2015

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment

artículo científico publicado en 2009

F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study

Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.

artículo científico publicado en 2018

Five-Year Outcomes for Frontline Brentuximab Vedotin with CHP for CD30 Expressing Peripheral T-Cell Lymphomas

artículo científico publicado en 2018

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

artículo científico publicado en 2017

Frontline Treatment with Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy for Classic Hodgkin Lymphoma: Updated Results and Correlative Analysis

Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma

artículo científico publicado en 2012

Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV

Genomic profiling for clinical decision making in lymphoid neoplasms

Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma

artículo científico publicado en 1992

Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.

artículo científico publicado en 2015

HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

artículo científico publicado en 2017

Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

artículo científico publicado en 2020

Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging

artículo científico

Hodgkin lymphoma

artículo científico publicado en 2011

Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines

artículo científico publicado en 2012

Hodgkin lymphoma, version 2.2015.

artículo científico publicado en 2015

How I treat nodular lymphocyte predominant Hodgkin lymphoma

artículo científico publicado en 2013

How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1 h: the Stanford Approach

artículo científico

Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience

artículo científico publicado en 2016

Ibrutinib in previously treated Waldenström's macroglobulinemia.

artículo científico publicado en 2015

Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management

artículo científico publicado en 2016

Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma

artículo científico publicado en 2020

Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia

scholarly article by Jorge J Castillo et al published October 2018 in Haematologica

Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease

artículo científico publicado en 2007

Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution.

artículo científico publicado en 2014

Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience

artículo científico publicado en 2013

Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center

artículo científico

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study

artículo científico publicado en 2011

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study

artículo científico publicado en 2010

Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas

scientific article published on 25 November 2019

Increased double-negative αβ+ T-cells reveal adult-onset autoimmune lymphoproliferative syndrome in a patient with IgG4-related disease

Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab

scientific article published on 24 September 2008

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study

artículo científico publicado en 2009

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

artículo científico publicado en 2017

Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease.

artículo científico publicado en 2012

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

artículo científico publicado en 2017

Investigating and modeling positron emission tomography factors associated with large cell transformation from low‐grade lymphomas

Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

artículo científico publicado en 2020

KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas.

artículo científico publicado en 2017

Lack of reproducibility of histopathological features in MYC ‐rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium

Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia

scientific article published on 15 September 2020

Long-Term Outcomes of Patients with Early-Stage Non-Bulky Hodgkin Lymphoma Treated with Combined Modality Therapy on the Stanford V Trials (The G4 and G5 Studies)

artículo científico publicado en 2020

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

artículo científico publicado en 2015

Long-term outcomes of patients with unfavorable stage I-II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation

artículo científico publicado en 2020

Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP).

artículo científico publicado en 2009

Lymphoma in pregnancy initially diagnosed as vaginal intraepithelial neoplasia and lichen planus.

artículo científico publicado en 2011

Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.

artículo científico publicado en 2013

Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation

artículo científico publicado en 2018

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines

artículo científico publicado en 2013

Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009.

artículo científico publicado en 2009

Management of advanced stage Hodgkin lymphoma

artículo científico publicado en 2006

Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.

artículo científico publicado en 2015

Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma

artículo científico publicado en 2014

MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.

artículo científico publicado en 2011

Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)

artículo científico publicado en 2004

Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma

scientific article published on 28 November 2018

Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma

article

Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.

artículo científico publicado en 2007

Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma

artículo científico publicado en 2012

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas

artículo científico publicado en 2010

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019

scientific article published on 01 June 2019

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017.

artículo científico publicado en 2017

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018

artículo científico publicado en 2018

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

artículo científico publicado en 2016

NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022

NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer.

artículo científico publicado en 2007

New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?

artículo científico publicado en 2018

Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria

artículo científico publicado en 2020

Non-Hodgkin lymphoma of the breast

artículo científico publicado en 2007

Non-Hodgkin's Lymphomas, version 3.2012

artículo científico publicado en 2012

Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology

artículo científico publicado en 2006

Non-Hodgkin's lymphomas

artículo científico publicado en 2008

Non-Hodgkin's lymphomas

artículo científico publicado en 2011

Non-Hodgkin's lymphomas, version 1.2013.

artículo científico publicado en 2013

Non-Hodgkin's lymphomas, version 2.2014

artículo científico publicado en 2014

Non-Hodgkin's lymphomas, version 4.2014.

artículo científico publicado en 2014

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.

artículo científico publicado en 2015

Novel Approaches in Waldenström Macroglobulinemia

artículo científico publicado en 2018

Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.

artículo científico publicado en 2014

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study

artículo científico publicado en 2016

Optimal Therapy of Advanced Hodgkin Lymphoma ⬇️

artículo científico publicado el 1 de enero de 2011

Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry

artículo científico publicado en 2019

Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.

artículo científico publicado en 2017

Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

scientific article published on 01 January 2020

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

Oxidation of hemoglobin F is associated with the aging process of neonatal red blood cells

artículo científico publicado en 1992

Oxidative red blood cell membrane injury in the pathophysiology of severe mouse beta-thalassemia ⬇️

artículo científico publicado el 15 de febrero de 1992

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

artículo científico publicado en 2016

Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.

artículo científico publicado en 2008

Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib

artículo científico publicado en 2020

Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma

artículo científico publicado en 2016

Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma

artículo científico publicado en 2020

Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network

artículo científico publicado en 2018

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies

artículo científico publicado en 2015

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).

scientific article published on 23 January 2014

Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

artículo científico publicado en 2016

Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies

artículo científico publicado en 2003

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma

artículo científico publicado en 2009

Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies

artículo científico publicado en 2010

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project

artículo científico publicado en 2015

Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer

artículo científico publicado en 2005

Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05).

artículo científico publicado en 2017

Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499

artículo científico publicado en 2012

Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.

artículo científico publicado en 2013

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

scientific article published on 29 March 2019

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies

artículo científico publicado en 2014

Postibrutinib outcomes in patients with mantle cell lymphoma

artículo científico publicado en 2016

Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment

artículo científico publicado en 2011

Primary Cutaneous Lymphomas

Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium

scientific article published on 09 September 2019

Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy

artículo científico publicado en 2018

Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome

artículo científico publicado en 2009

Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium.

artículo científico publicado en 2017

Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial

artículo científico publicado en 2015

Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)

artículo científico publicado en 2012

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

artículo científico publicado en 2016

Reply to J. Wang et al

scientific article published on 12 February 2019

Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma

Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404)

artículo científico publicado en 2015

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.

artículo científico publicado en 2014

Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials

artículo científico publicado en 2013

Risk stratification in extranodal natural killer/T-cell lymphoma

artículo científico publicado en 2010

Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT.

artículo científico publicado en 2016

Risk-adapted therapy for advanced-stage Hodgkin lymphoma

artículo científico publicado en 2018

Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.

artículo científico publicado en 2015

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

artículo científico publicado en 2012

Sequential Pembrolizumab and AVD is Highly Effective at any PD-L1 Expression Level in Untreated Hodgkin Lymphoma

Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines

artículo científico publicado en 2012

Speeding up PET/MR for cancer staging of children and young adults

artículo científico publicado en 2016

Splenic diffuse large B-cell lymphoma in a patient with type 1 Gaucher disease: Diagnostic and therapeutic challenges

artículo científico publicado en 2006

Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy

scientific article published on 15 March 2004

Stage I-II Nodular Lymphocyte-Predominant Hodgkin Lymphoma: a Multi-institutional Experience of Adult Patients by ILROG

artículo científico publicado en 2020

Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience

artículo científico publicado en 2010

Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography

artículo científico publicado en 2006

Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.

artículo científico

Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).

artículo científico publicado en 2010

T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma

artículo científico publicado en 2020

Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell Lymphomas

Targeted therapy in relapsed classical hodgkin lymphoma

artículo científico publicado en 2013

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.

artículo científico publicado en 2015

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

artículo científico publicado en 2013

Targeting CD40 in Waldenström's macroglobulinemia

artículo científico publicado en 2009

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

artículo científico publicado en 2016

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified.

artículo científico publicado en 2016

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

artículo científico publicado en 2016

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group

artículo científico publicado en 2018

The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma

artículo científico publicado en 2020

The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496

artículo científico publicado en 2013

The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma

scientific article published on September 2009

The landscape of new drugs in lymphoma

artículo científico publicado en 2016

The outcome of peripheral T-cell lymphoma patients failing first line therapy: a report from the prospective, international T-Cell project.

artículo científico publicado en 2018

The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study

scientific article published on 29 January 2019

Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

artículo científico publicado en 2020

Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma

Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine

artículo científico publicado en 1997

Treatment of mantle cell lymphoma: current approach and future directions

artículo científico publicado en 2006

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus

artículo científico publicado en 2014

Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia

artículo científico publicado en 2016

Trial in Progress: First Report of the Phase 1/2 Study of the Safety and Efficacy of CPO107, a Bispecific Agent Targeting CD20/CD47 in CD20 Expressing Non-Hodgkin Lymphoma (NHL)

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial

artículo científico publicado en 2012

Updates in Treatment Strategies for Hodgkin Lymphoma

scientific article published on 01 November 2019

Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients With Classic Hodgkin Lymphoma in First Remission: Results From a Large Single-Institution Study

artículo científico publicado en 2020

Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.

artículo científico publicado en 2015

Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas

Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules

artículo científico publicado en 2010

XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma

artículo científico

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda